Skip to main content
ResearchTreatments

PALOMA-3: Subcutaneous Amivantamab in Refractory EGFR+ Advanced NSCLC

*June 2024*

In this video, experts provide perspectives (and pros and cons) on recent data from the PALOMA-3 study investigating subcutaneous amivantamab in patients with refractory EGFR-mutated advanced non–small cell lung cancer. Watch here.
Share